Students' knowledge of COPD: projects ASCO-1 and ASCO-2 results comparison

被引：0
|
作者：
Bontsevich, Roman [1 ]
Filinichenko, Tatyana [1 ]
Gavrilova, Anna [1 ]
Shchurovskaya, Kristina [1 ]
Batisheva, Galina [2 ]
Goncharova, Natalya [2 ]
Ketova, Galina [3 ]
Barysheva, Valeriya [3 ]
Myronenko, Olena [4 ]
Kompaniets, Olga [5 ]
Miliutina, Elena [1 ]
Mikhno, Alina [6 ]
Zhdanova, Zhanna [1 ]
机构：
[1] Belgorod State Natl Res Univ, Belgorod, Russia
[2] Voronezh State Med Univ, Voronezh, Russia
[3] South Ural State Med Univ, Chelyabinsk, Russia
[4] Dnipropetrovsk Med Acad, Dnipro, Ukraine
[5] Kuban State Med Univ, Krasnodar, Russia
[6] LLC MAKSBelmed, Belgorod, Russia
来源：
EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷
关键词：
COPD; Education;
D O I：
10.1183/13993003.congress-2019.PA1485
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA1485
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines
    Nagarjun, B. R.
    Parikh, Biren
    Patel, Manaswi Nareshkumar
    Trivedi, Pina J.
    Patel, Dharmesh M.
    SOUTH ASIAN JOURNAL OF CANCER, 2022, 11 (04) : 281 - 286
  • [42] The myth of ASCOT and its rival ASCO(2). T: Tech-noetic vs. techno-logic, round 1
    Ljubec, Ziva
    TECHNOETIC ARTS, 2012, 9 (2-3) : 89 - 96
  • [43] Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases
    Zhi-Hua Liu
    Kun Wang
    Dan-Yi Lin
    Jie Xu
    Jie Chen
    Xiao-Yu Long
    Yan Ge
    Xin-Lan Luo
    Ke-Ping Zhang
    Yan-Hui Liu
    Fang-Ping Xu
    Breast Cancer Research and Treatment, 2019, 175 : 51 - 57
  • [44] Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases
    Liu, Zhi-Hua
    Wang, Kun
    Lin, Dan-Yi
    Xu, Jie
    Chen, Jie
    Long, Xiao-Yu
    Ge, Yan
    Luo, Xin-Lan
    Zhang, Ke-Ping
    Liu, Yan-Hui
    Xu, Fang-Ping
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (01) : 51 - 57
  • [45] Use of 2013 ASCO-CAP Breast Carcinoma HER2 Scoring Guidelines Results in Shifts of Scoring Categories With Slight Change in IHC-FISH Concordance
    Fulton, Regan
    Gown, Allen
    MODERN PATHOLOGY, 2015, 28 : 45A - 45A
  • [46] Low rates of BRCA1 and BRCA2 testing for patients with ovarian cancer in ASCO's CancerLinQ, a real-world database.
    Dewdney, Summer
    Potter, Danielle
    Haidle, Joy Larsen
    Hulick, Peter J.
    Riffon, Mark
    Monzon, Federico A.
    Keole, Sameer R.
    Miller, Robert S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1
    Ettl, Johannes
    Klein, Evelyn
    Hapfelmeier, Alexander
    Lackmann, Kirsten Grosse
    Paepke, Stefan
    Petry, Christoph
    Specht, Katja
    Wolff, Laura
    Hoefler, Heinz
    Kiechle, Marion
    PLOS ONE, 2017, 12 (09):
  • [48] Use of 2013 ASCO-CAP Breast Carcinoma HER2 Scoring Guidelines Results in Shifts of Scoring Categories With Slight Change in IHC-FISH Concordance
    Fulton, Regan
    Gown, Allen
    LABORATORY INVESTIGATION, 2015, 95 : 45A - 45A
  • [49] Comparison of IHC testing for HER-2 in breast cancer specimens before and after adoption of new 2013 ASCO/CAP guidelines in a single institution: Impact on outcome and cost
    Sharma, Anurag
    Hegde, Poornima
    Vadehra, Deepak
    Kaiser, Talal
    Tannenbaum, Susan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] The Impact of 2018 ASCO-CAP HER2 Testing Guidelines on Breast Cancer HER2 Results. An audit of 2136 consecutive cases evaluated by Immunohistochemistry and In Situ Hybridization
    Farshid, Gelareh
    Dhatrak, Deepak
    Gilhotra, Amardeep
    Koszyca, Barbara
    Nolan, James
    LABORATORY INVESTIGATION, 2019, 99
12345